Thermo Fisher Scientific (TMO)

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...

Life sciences company Thermo Fisher (NYSE:TMO) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 9.1% year on year to $12.14...

Strategic acquisitions are deepening customer relationships while AI integration boosts lab productivity, positioning the company for durable margin expansion.

Adjusted EPS surged 15% as revenue hit $12.14 billion.

Thermo Fisher Scientific (NYSE:TMO) reported third-quarter revenue growth of 9% to $12.14 billion, supported by 6% organic growth, acquisitions and foreign-exchange effects. Adjusted earnings per share rose 15% to $6.68, while adjusted operating income increased 15% to $2.97 billion. Chairman and C

Life sciences company Thermo Fisher (NYSE:TMO) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 9.1% year on year to $12.14...

Life sciences company Thermo Fisher (NYSE:TMO) will be reporting results this Wednesday before the bell. Here’s what investors should know. Thermo Fisher bea...

Biotech stocks trade on FDA trial phases. Phase 2 data often builds value, cash runway limits dilution, and Quantum BioPharma just began a phase 2 MS trial.

Thermo Fisher’s 36.4% return over the past six months has outpaced the S&P 500 by 20.1%, and its stock price has climbed to $652.30 per share. This was partl...

Thermo Fisher Scientific (NYSE:TMO) Chairman and Chief Executive Officer Marc Casper said the company is seeing improving demand across several end markets and expects 2026 to be an “outstanding year,” supported by stronger customer activity and operational execution. Speaking at Morgan Stanley’s G

Thermo Fisher Scientific (NYSE:TMO) has outperformed the market over the past 15 years by 4.35% on an annualized basis producing an average annual return of 17.57%. Currently, Thermo Fisher Scientific has a market

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...

Thermo Fisher Scientific (NYSE:TMO) has outperformed the market over the past 10 years by 1.87% on an annualized basis producing an average annual return of 15.26%. Currently, Thermo Fisher Scientific has a market

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how research tools & consu...

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Thermo Fisher Scientific (NYSE:TMO) has outperformed the market over the past 10 years by 1.15% on an annualized basis producing an average annual return of 14.61%. Currently, Thermo Fisher Scientific has a market

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...